Potent CBP/p300 bromodomain (BRD) inhibitor (Kd
values are 21 and 32 nM for CBP and p300 BRDs respectively). Exhibits 40-fold and 250-fold selectivity for CBP over the first BRD of BRD4 (BRD4(1)) and BRD4(2) respectively. Accelerates FRAP recovery in cells at a concentration of 1 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the SGC-CBP30 probe summary
on the SGC website.
Bromodomains and their pharmacological inhibitors.
Gallenkamp et al.
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay et al.